$\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ection 16. Form 4 or Form 5 bligations may continue. See	to
	theck this box if no longer subject the tection 16. Form 4 or Form 5 bligations may continue. See instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPF	ROVAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response.	0.5

1. Name and Address of Reporting Person* <u>MURRAY RICHARD /CA/</u>			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>PDL BIOPHARMA, INC.</u> [ PDLI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) ( C/O PROTEIN DESIGN LABS, INC 34801 CAMPUS DRIVE		(Middle) BS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 07/13/2006	X Officer (give title Other (specify below) Sr. VP & CSO
(Street) FREMONT (City)	CA (State)	CA 94555	<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> </ul>	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities J Disposed Of 5)			Securities	(D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)
Common Stock	07/13/2006		<b>F</b> <sup>(1)</sup>		1,448	D	\$17.4	37,572	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/)	7. Title Amour Securi Underl Deriva Securi and 4)	nt of ties ying tive ty (Instr. 3	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents the number of shares withheld by the issuer and canceled to satisfy tax withholding obligations of the reporting person that arose on the transaction date in connection with the vesting of restricted shares of common stock.

## Remarks:

<u>/s/ George Jue by George Jue,</u> <u>Attorney in Fact for Richard</u> 07/17/2006 <u>Murray</u> \*\* Signature of Reporting Person Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.